Viability of bifidobacteria in yogurts containing oat beta-glucan and/or corn starch during cold storage by Rosburg, Valerie Ann
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2009
Viability of bifidobacteria in yogurts containing oat
beta-glucan and/or corn starch during cold storage
Valerie Ann Rosburg
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Nutrition Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Rosburg, Valerie Ann, "Viability of bifidobacteria in yogurts containing oat beta-glucan and/or corn starch during cold storage"
(2009). Graduate Theses and Dissertations. 11050.
https://lib.dr.iastate.edu/etd/11050
  
Viability of bifidobacteria in yogurts containing oat beta-glucan and/or corn starch 
during cold storage 
   
 
by 
 
 
Valerie Ann Rosburg 
 
 
 
 
A thesis submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
MASTER OF SCIENCE 
 
 
 
 
Major:  Food Science and Technology 
 
Program of Study Committee: 
Pamela J. White, Major Professor 
Terri Boylston 
Sarah Nusser 
 
 
 
 
 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2009 
 
Copyright © Valerie Ann Rosburg, 2009.  All rights reserved. 
 
 ii
TABLE OF CONTENTS 
 
          
CHAPTER 1:  INTRODUCTION          1 
 General Introduction           1 
 Thesis Organization           2 
 Literature Review           3 
 References          18 
 
CHAPTER 2:  VIABILITY OF BIFIDOBACTERIA STRAINS IN YOGURT WITH 26 
ADDED BETA-GLUCAN AND CORN STARCH DURING COLD STORAGE  
Abstract          26 
 Introduction          27 
 Materials and Methods        29 
 Results and Discussion        33 
 Conclusion          38 
 Acknowledgments         38 
 References          38 
 Tables and Figures         41 
 
CHAPTER 3:  GENERAL CONCLUSIONS      47 
 
APPENDIX 1: SURVIVAL OF BIFIDOBACTERIA IN LIQUID MEDIA WITH  49  
ADDED BETA-GLUCAN DURING COLD STORAGE  
 
APPENDIX 2: SURVIVAL OF BIFIDOBACTERIA WITH ADDED   54 
BETA-GLUCAN THROUGH A SIMULATED GASTRIC SYSTEM  
 
ACKNOWLEDGMENTS         60 
 
 
 
 
 
 
 
 
1 
 
INTRODUCTION 
 
GENERAL INTRODUCTION 
 
Beta-glucan, a soluble dietary fiber found in high concentration in oats and a known 
prebiotic, has many desirable physical and physiological characteristics.  Beta-glucan has 
been shown to relieve constipation, reduce the risk of colorectal cancer, attenuate post 
prandial blood sugar, assist in the production of short chain fatty acids and promote the 
growth of beneficial gut microflora.  However the most widely accepted benefit of beta-
glucan is its ability to reduce serum cholesterol.  Because of this significant physiological 
benefit, in 1997 the FDA approved a health claim for beta-glucan stating that when 
consumed in sufficient amounts, beta-glucan can reduce the risk of heart disease.  Physically, 
beta-glucan is recognized to improve the texture and mouthfeel of low-fat dairy foods by 
acting as a fat mimetic. Therefore, beta-glucan is of great importance in both the medical 
field and food industry. 
Bifidobacteria, beneficial bacteria with well known probiotic activity, have many 
known health benefits.  These include prevention of diarrhea, positive immunomodulation, 
improved gut transit time, colon cancer prevention, and increased mineral absorption.  In 
order to reap the benefits of bifidobacteria, they must be consumed at a level of 107 viable 
cells per ml or g of food.  However, bifidobacteria often drop below this therapeutic level 
during refrigerated storage due to a host of factors that include pH, oxygen content, and 
osmotic pressure.  In order to alleviate these stressors many techniques have been tested, 
including the addition of a prebiotic to the food.      
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Little is known about the effects of prebiotics, such as oat beta-glucan, on probiotic 
cultures survival outside of the gut, specifically during refrigerated storage before 
consumption.  Cold storage is a critical time during the lifespan of a yogurt product as 
bacterial strains can be very cold liable.  It is important to understand how cold effects 
probiotic strains in order to prevent significant probiotic decrease below a therapeutic level 
before a consumer purchases and consumes a yogurt product. 
The objectives of this study were to evaluate the effect of two oat beta-glucan 
preparations, a modified corn starch and the combination of beta-glucan and corn starch on 
the survival of two bifidobacteria strains, as well as yogurt culture strains, during five weeks 
of storage at 4 °C.  To achieve this objective, yogurts were created containing yogurt 
cultures, a beta-glucan or starch treatment, and one strain of bifidobacteria.  The yogurts 
were fermented and stored at 4 °C for five weeks with aliquots taken weekly for bacterial 
enumeration.  
 
THESIS ORGANIZATION 
 
 This thesis is organized in three chapters.  The first chapter contains a general 
introduction of the subject material as well as a review of the peer-reviewed literature 
concerning the topic.  The second chapter is a manuscript to be submitted to the Journal of 
Food Science, and contains a complete report of the research completed.  The third chapter 
contains a general conclusion.  Finally, there are two appendices located at the end of the 
thesis that give a brief overview of preliminary experiments designed to help understand the 
mechanisms for the observations noted in the manuscript.  Although these findings were 
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inconclusive, they contain relevant information as it pertains to the primary study.  After each 
chapter there is a list of references cited within that chapter.    
 
 
LITERATURE REVIEW 
 
BETA-GLUCAN 
 
Beta-glucan is one of the major components of the starchy endosperm and aleurone 
cell walls of many commercially important cereal grains, such as oats, barley, rye and wheat 
(Lazaridou and Biliaderis 2007).  Beta-glucan is composed of polymers of glucose connected 
by approximately 70% β-(1-4) and 30% of β-(1-3) linkages.  The interruption of β-(1-4) 
linkages with β-(1-3) linkages makes beta-glucan much more flexible, soluble, and viscous 
than cellulose (Liu 2007).   Beta-glucan content can range from 1% in wheat, 3-7% in oats 
and 5-11% in barley (Skendi and others 2003).  Although the structure of beta-glucan is very 
similar between different genera of cereals, there is growing evidence that oat, barley and 
wheat beta-glucans are structurally distinct as determined by HPLC analysis of lichenase-
released oligosaccharides (Lazaridou and Biliaderis 2007).  This difference seems to lie 
within the relative amount of trisaccharide (cellotriosyl (DP3) and tetrasaccharide 
(cellotetraosyl (DP4)) produced by the lichenase action.  Wheat has the greatest percentage 
of DP3 and lowest percentage of DP4, whereas oat has the lowest percentage of DP3 and the 
highest percentage of DP4.  Barley distribution lies between those of wheat and oat 
(Lazaridou and Biliaderis 2007).   
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HEALTH BENEFITS 
 
Cholesterol effects 
Although there seem to be minor differences in the structure of beta-glucan 
originating from different species, the benefits associated with the consumption of beta-
glucan are universal.  Beta-glucan is classified as a soluble dietary fiber.  According to the 
American Association of Cereal Chemists, dietary fiber ‘is the edible parts of plants or 
analogous carbohydrates that are resistant to digestion and adsorption in the human small 
intestine with complete or partial fermentation in the large intestine.  Dietary fiber includes 
polysaccharides, oligosaccharides, lignin and associated plant substances.  Dietary fibers 
promote beneficial physiological effects, including laxation, and /or blood cholesterol 
attenuation, and/or blood glucose attenuation’ (DeVries 2001).  In addition, beta-glucan, as a 
component of dietary fiber, provides additional health benefits, including relief from 
constipation, reduction of risk of colorectal cancer, production of short-chain fatty acids, and 
promotes the growth of beneficial gut microflora (Bingham 1990; Karppinen and others 
2000; Crittenden and others 2002).  The most widely accepted benefit of the consumption of 
beta-glucan is the lowering of serum cholesterol.  Results from studies using oat beta-glucan 
have shown an average reduction by 10% for total cholesterol and 8% for LDL cholesterol 
accompanied by a 16% elevation in HDL cholesterol after 4 weeks of consumption of a 1% 
(w/w) beta-glucan extract (Liu 2007; Behall and others 1997; Bell and others 1999). 
 
5 
 
There are many proposed mechanisms to account for how consumption of beta-
glucan is able to lower cholesterol.  The first, and most widely accepted, mechanism states 
that soluble fiber provides a very viscous environment in the intestinal lumen that is able to 
bind to bile acids in the intestine resulting in a total decrease in the available bile-acid pool 
that circulates back to the liver.  The reduction in available bile stimulates the production of 
more bile acids which are derived from cholesterol either endogenously produced or 
adsorbed from circulation after a meal (Bell and others 1999).  This binding action may also 
facilitate cholesterol elimination from the body (Liu 2007).  In addition, the increased 
viscosity caused by beta-glucan may affect lipid emulsification by increasing the emulsion 
droplet size which may impair fat adsorption thus decreasing cholesterol adsorption 
(Pasquier and others 1996).   A second theory accounts for interaction of beta-glucan with 
gut microflora.  As soluble fibers are fermented in the large intestine by colonic bacteria, 
short-chain fatty acids are produced.  Short-chain fatty acids are taken up by the portal vein 
which inhibits hepatic cholesterol synthesis by way of limiting the action of HMG-CoA 
reductase or increasing the catabolism of LDL (Bell and others 1999).  However this effect 
has only been confirmed for one of the short-chain fatty acids, propionate (Bell and others 
1999).  A third mechanism may involve the ability of beta-glucans  to delay gastric emptying 
which reduces post-prandial insulin levels, in turn reducing hepatic cholesterol synthesis 
though mediation of HMG-CoA reductase (Bell and others, 1999). 
 
In 1995, the Quaker Oats Company petitioned the FDA for permission to make a 
health claim that oat products may reduce the risk of heart disease.  This petition was granted 
in January of 1997.  The FDA claim states that “soluble fiber from oatmeal, as part of a low 
6 
 
saturated fat, low-cholesterol diet, may reduce the risk of heart disease” (FDA 1997).  The 
FDA stated as part of the health claim that 3 g of beta-glucan per day lowers blood 
cholesterol.  More specifically, the claim only relates to oat products that contain at least 0.75 
g of beta-glucan per serving.  
 
Blood sugar 
Another well studied health benefit associated with the consumption of beta-glucan is 
its ability to attenuate post-prandial hyperglycemia and insulin response.  In one study, 
frequent meals with or without beta-glucan resulted in similar carbohydrate metabolism, but 
ingestion of a single meal containing beta-glucan resulted in lowered post-prandial glucose 
concentrations (Battilana and others 2001) .  These results suggest that beta-glucan may 
delay and reduce carbohydrate adsorption from the gut.  It is also well known that the 
increased viscosity of the intestinal environment associated with beta-glucan consumption 
reduces digestion of carbohydrates by alpha-amylase.  The addition of 5% of a beta-glucan-
rich fraction in bread significantly reduced the release rate of reducing sugars after an in vitro 
digestion with pepsin and alpha-amylase (Symons and Brennan 2004).  Beta-glucans may 
reduce the accessibility of starch degradation enzymes to their substrates by forming a gel 
matrix or by eliminating the water available for starch hydration and gelatinization 
(Lazaridou and Biliaderis 2007). 
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FUNCTIONAL FOODS 
 
Because of the health claims associated with beta-glucan consumption, foods with 
incorporated beta-glucan are in demand as functional foods.  Beta-glucans, as mentioned 
earlier, have unique rheological characteristics, such as the ability to gel and to increase the 
viscosity of aqueous solutions, which contributes to their health benefits.  These same unique 
rheological characteristics can be used to benefit food products as well.  When developing 
formulations that include beta-glucan it is important to consider not only the benefits but the 
problems that can arise with adding a sufficient amount to the food product to produce the 
desired physiological benefits without altering the food texture to a point where it would 
become unpalatable.  
 
 Commercial beta-glucan preparations   
As a result of the health benefits of beta-glucan, there have been quite a few efforts to 
extract them on large scale for commercial use.  There are a series of products with the suffix 
‘trim’ which is an acronym for ‘technical research involving metabolism’  that contain 
varying amounts of beta-glucan invented by Dr. George Inglett at the USDA ARS 
Biopolymer Research Unit in Peoria, IL, USA (Harris and Smith 2006).  One of these 
products, Oatrim, contains 5-10% beta-glucan and is made from oat bran or oat flour treated 
with thermostable alpha-amylase (Inglett 1993).  Oatrim also contains small amounts of 
amylodextrins, lipid, protein and minerals (Inglett 1993).  The most recent ‘trim’ product is 
C-trim which is prepared by steam-jet cooking and fractionating oat bran.  Its beta-glucan 
concentration ranges from 15-30% (Lee and others 2005).  Beta-glucan contained in the 
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‘trim’ preparations lower blood cholesterol and glucose concentrations, however Glucogel 
does not seem to provide these health benefits which may be due to the partial hydrolysis of 
the beta-glucans during extraction (Harris and Smith 2006).  Recently, a very successful 
method has been developed for the extraction of beta-glucan from oat flour and the addition 
of this water soluble fiber to dairy products (Yao and White 2008).     
 
Addition of Beta-glucan to Foods  
Because of their ability to increase viscosity of aqueous solutions, beta-glucans can 
be used as thickening agents or as fat mimetics in the formulation of reduced calorie foods.  
They can control food texture and have been used to replace all or part of the fats in dairy, 
meat, and bakery products (Harris and Smith 2006).  C-trim is used in the preparation of a 
low-fat cheddar cheese, and Glucogel can create edible films to control water transfer and 
improve shelf-life (Harris and Smith 2006; Morgan and Ofman 1998).   
 
One of the largest areas for potential use of beta-glucan is in the dairy industry.  
Incorporation of beta-glucan with other soluble fiber into low-fat dairy products, such as ice-
cream and yogurts, can improve their mouthfeel, scoopability and other sensory properties to 
more closely resemble full-fat products (Brennan and Cleary 2005).  In addition, when beta-
glucan is added to milk, the curd cutting time is reduced and  curd yields are increased as a 
result of its ability to form a structured and elastic casein-protein-glucan matrix (Tudorica 
and others 2004).  For example, an oat beta-glucan added to a low-fat white brined cheese at 
0.7 and 1.4%, reduced the hardness of the cheese and lead to a product that more closely 
resembled the full-fat control (Volikakis and others 2004). 
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Because of the ability of beta-glucan to attenuate the glycemic response, there is 
much interest in incorporating beta-glucan into cereal-based products, such as pasta and 
breads.  Recently, incorporation of high MW beta-glucans at 0.6% w/w improved the bread-
making quality, specifically loaf volume, of a poor bread-making wheat cultivar that 
exceeded the quality of a good bread-making wheat cultivar (Lazaridou and Biliaderis 2007).  
The addition of beta-glucan of up to 5% into baked goods seems to show no affect on the 
overall acceptability of the products (Lazaridou and Biliaderis 2007).  Furthermore, up to a 
20% addition of barley beta-glucan to semolina or wheat flours produced pasta and noodles 
with acceptable sensory and cooking qualities; they did, however, have reduced brightness 
and yellowness and increased redness and ‘speckiness’ compared to the control (Hatcher and 
others 2005).   
 
The addition of beta-glucan preparations also improved the quality of egg-yolk-
stabilized emulsions, reduced-fat breakfast sausages, and lactose-free, non-dairy milk 
substitutes such as yogurt, ice-cream, oat-based cream, whipped cream and buttermilk 
(Lazaridou and Biliaderis 2007).  In reduced-fat breakfast sausages, the addition of 0.3 % 
beta-glucan improved water binding without significant effects on product texture or flavor 
(Morin and others 2002).  Additionally, the  non-dairy milk substitutes listed previously 
benefit from the addition of beta-glucan as stabilizers and texturizers (Lazaridou and 
Biliaderis 2007)  
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INULIN  
 
Inulin, a dietary fiber, is composed of a mixture of fructose chains that vary in length 
(from 2-60 fructose units) and have a terminal glucose residue (Niness 1999).  Inulin is 
typically isolated in high amounts from chicory root, but also is found in artichoke, leek, 
onion, asparagus, wheat, barley, rye, garlic and bananas (Liu 2007).  Inulin is the primary 
source of added dietary fiber in food products.  It is often added to foods because of its sweet 
taste and desirable texture.  Inulin is best noted for acting as a prebiotic.  When ingested at a 
level of 15 g per day for 15 consecutive days, inulin was shown to increase the population of 
bifidobacteria, a probiotic, by 10% with a concomitant decrease in pathogenic bacteria (Liu 
2007).  Although similar to beta-glucan, in that it is a dietary fiber, inulin has not been 
recognized with an FDA health claim.      
 
BIFIDOBACTERIA 
 
Bifidobacteria are gram-positive, anaerobic bacteria that grow at temperatures 
between 37-41°C and at a pH between 6.5-7.0 (Sneath and others 1986).  They are non-
motile, nonspore-forming rods that show branching, bends, and protuberances, but can vary 
widely in morphology (Sneath and others 1986).  Bifidobacteria naturally occur in the gut of 
both humans and animals and were first isolated from the feces of breastfed infants, in which 
it predominates, by Tissier in 1899 (Shah and Lankaputhra 2002).  It is thought that breast 
milk provides the optimum combination of oligosaccharides that allow for bifidobacteria to 
flourish (Veereman 2007).   
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Although bifidobacteria predominate in the guts of infants, with age, they are soon 
joined by a variety of other bacteria such as E. coli, lactobacilli and clostridia that eventually 
outnumber bifidobacteria (Candy and others 2008).  Gut colonization by bifidobacteria has 
been shown to fall in adults by 1000-fold after age 60 (van Tongeren and others 2005).  A 
drop in bifidobacteria in the elderly is accompanied by an increase in less desirable 
Enterobacteriaceae, and this change in gut microbiota is associated with increased frailty 
(van Tongeren and others 2005).  The shift in gut ecology with age draws attention to the role 
of bifidobacteria as a part of intestinal flora and its role in maintaining overall health and 
well-being. 
 
Bifidobacteria are commonly called probiotics.  Probiotics are defined as “a 
preparation of or a product containing viable, defined microorganisms in sufficient numbers, 
which alter the microflora (by implantation or colonization) in a compartment of the host and 
by that exert beneficial health effects in this host” (Schrezenmeir and de Vrese 2001).  Many 
strains of bifidobacteria have been investigated for possible health benefits.  Some of their 
better documented health benefits include decreasing frequency and duration of antibiotic 
associated diarrhea as well as positive immunomodulatory activity (Schrezenmeir and de 
Vrese 2001).   
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HEALTH BENEFITS 
 
Prevention and Alleviation of Diarrhea 
When the ecology of the gut is disrupted, as is the case with antibiotic treatment, the 
affect is often acute diarrhea.  It is estimated that as many as 39% of patients who receive 
antibiotics will suffer from antibiotic-associated diarrhea (Surawicz 2003).  This side affect 
occurs as a result of the death of beneficial bacteria, which are reduced in number by 
antibiotic treatment, leaving opportunity for the growth of strains such as Clostridium.  Toxin 
production by Clostridium difficile is a serious and often common cause of antibiotic-
associated diarrhea (Surawicz 2003).  The probiotic actions of bifidobacteria continue to be 
investigated as a remedy for antibiotic associated diarrhea.   Several studies have shown a 
reduction in both frequency and duration of antibiotic-associated diarrhea by Bifidobacterium 
longum (Colombel and others 1987; Orrhage and others 1994).  Additionally, 
Bifidobacterium bifidum has been found to participate in toxin neutralization, which 
consequently leads to a reduction in the incidence of antibiotic-associated diarrhea (Plummer 
and others 2004).   
 
Another common cause of diarrhea is exposure to a variety of pathogenic bacteria 
while traveling.  Some of the more common strains involved in traveler’s diarrhea include 
Escherichia coli, Salmonella, Campylobacter and Shigella strains (Ericsson 2003).  In a 
study done with Egyptian tourists, Bifidobacterium bifidum, in combination with S. 
thermophilus, L. bulgarius and L. acidophilus, was shown to reduce the frequency of 
traveler’s diarrhea from 71 to 43% (Black and others 1989).  Rotavirus is a major cause of 
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diarrhea in infants and young children.  When children were given B. bifidum in conjunction 
with S. thermophilus in formula, incidence of rotaviral infection was reduced (Saavedra and 
others 1994).  In addition, B. breve was shown to inhibit the infectivity of rotavirus (Bae and 
others 2002).  Finally, B. lactis strain Bb 12 when added to acidified formula, has been 
shown to have a protective effect against acute diarrhea in healthy children (Chouraqui and 
others 2004).  All of these findings show potential for the use of bifidobacteria for the 
treatment and/or prevention of a variety of illnesses with associated diarrhea. 
 
Immunomoduation 
The gastrointestinal tract serves its main functions in absorption and digestion, 
however it is also the body’s largest organ of host defense against antigens and the 
microflora of the gut are an essential part of this protection (Servin 2004).  The addition of 
bifidobacteria can then either directly or indirectly affect the function of the gut barrier.  
Although the investigation of bifidobacteria’s role in host protection is in its infancy, there 
are many proposed mechanisms as to how bifidobacteria are able to impart positive 
immunomodulatory effects.  One commonly proposed mechanism states that colonization of 
bifidobacteria in the gut out-competes colonization by viruses or bacteria and is known as the 
barrier effect.  Other mechanisms include production of inhibitory substances, blockade of 
adhesion sites, and stimulation of immunity.  A variety of bifidobacteria stains have been 
found to produce and secrete inhibitory substances, including a protein factor produced by 
Bifidobacterium longum with a molecular weight of 100,000 that inhibited the adhesion of an 
entrotoxigenic E. coli strain to the intestinal mucosa (Fujiwara and others 1997).  Similarly, 
bifidobacteria strains have been shown to produce antimicrobial compounds that inhibit the 
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growth of pathogens (Lievin and others 2000).  Bifidobacteria may also provide improved 
gut barrier function by blocking epithelial adhesion sites from pathogenic viruses or bacteria 
(Picard and others 2005).  Finally, bifidobacteria strains have been shown to stimulate 
immunity.  Immune stimulation by bifidobacteria is accomplished by stabilizing the intestinal 
mucosa and normalizing intestinal permeability which decreases the overgrowth of 
pathogens (Picard and others 2005).  Examples of immune stimulation include the ability of 
B. longum to increase the defensive functions of germ-free mice and B. breve to enhance the 
antigen specific IgA-antibody towards rotavirus in mice (Yamazaki and others 1985; Yasui 
and others 1995).   
 
 
Improved Transit Time 
There is evidence that bifidobacteria are able to prevent and/or relieve constipation by 
increasing gut transit time.  The ability of bifidobacteria to speed gut transit time has been 
shown in a number of human studies.  One such study found that the ingestion of 125 g/day 
of  bifidobacterium-fermented milk reduced their oro-fecal transit time by 20-42% on 
average with the effect lasting from 2-4 weeks after cessation of the bifidobacterium-
fermented milk ingestion (Bouvier and others 2001).  The most common theory is that 
bifidobacteria, which are able to produce short-chain fatty acids in the gut, lower the pH of 
the intestinal lumen which, in turn, stimulates intestinal peristalsis, thus decreasing transit 
time (Candy and others 2008).  A second theory is that bifidobacteria are able to improve 
transit time by increasing the fecal bacterial mass and bacterial metabolism of bile acids in 
the colon (Candy and others 2008).  Finally, a third theory links improved transit time to the 
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stimulation of cholecystokinin which increases the stimulatory response of the smooth 
muscle of the gut (Candy and others 2008).   
 
Cancer prevention 
Colorectal cancer is the third most common cancer in men and women within the 
United States (U.S.C.S. 2007).  Furthermore, a great percentage of human tumors are 
reported to be related to dietary habits (Zubillaga and others 2001).  Certain strains of both 
lactic acid-producing bacteria as well as bifidobacteria that are used to ferment milk may be 
very promising antimutagenic and anticarcinogenic candidates (Zubillaga and others 2001).  
In a study done to investigate the relationship between ingestion of viable bifidobacteria and 
the incidence of aberrant crypts, which are precursor lesions of colon cancer, a diet including 
milk fermented by bifidobacteria reduced the incidence of aberrant crypts by 49% when 
compared to the control diet (Abdelali and others 1995).  Thus, evidence is mounting that 
intestinal flora can impact carcinogenesis.  Carcinogenesis as it relates to intestinal flora is 
hypothesized to be a result of the production of enzymes, such as β-glucuronidase, 
azoreductase and nitroreductase, by the bacteria that transform procarcinogens to active 
carcinogens (Picard and others 2005).  There is some evidence that bifidobacteria may 
protect the host from carcinogens by reducing the production of carcinogens by way of 
reducing specific enzyme activity.  In two similar studies, consumption of milk fermented 
with bifidobacteria lead to decreased β –glucuronidase and nitroreductase activity in humans 
(Marteau and others 1990; Bouhnik and others 1996).   
 
16 
 
Mineral Absorption and bone density 
Recently, the consumption of bifidobacteria has been linked to improved intestinal 
mineral absorption and increased bone density.  In a recent study, the oral application of 
Bifidobacterium longum was correlated with increased bone breaking strength in an 
osteoporosis rat model (Igarashi and others 1994).  It is believed that increased bone breaking 
strength as it relates to bifidobacteria is the result of improved mineral adsorption and bone 
density.  There are several factors possibly contributing to increased bone density, including 
increased mineral solubility as a result of increased bacterial production of short-chain fatty 
acids, enlargement of the adsorption surface by the proliferation of enterocytes which is 
mediated by the bacterial fermentation products lactate and butyrate, and increased 
expression of calcium binding proteins (Scholz-Ahrens and others 2007).  Improved bone 
density may be a result of  production, by probiotics, of vitamins such as C, D, K and folate 
involved in calcium metabolism (Scholz-Ahrens and others 2007).   
 
VIABILITY OF BIFIDOBACTERIA IN FOODS 
 
 Yogurt, a fermented dairy food produced by the action of cultures of lactic acid 
bacteria, is produced and consumed worldwide and has been targeted as an ideal carrier for 
probiotic microorganisms, such as bifidobacteria, due to its ability to reach many consumers 
(Lourens-Hattingh and Viljoen 2001).  It has been widely suggested, to achieve therapeutic 
benefits of bifidobacteria and other probiotic organisms, that consumption of the probiotic 
must be at least 107 viable cells per ml or g of product (Lourens-Hattingh and Viljoen 2001). 
Although bifidobacteria are easily added to dairy products such as yogurt their survival, 
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particularly during refrigerated storage of the food, is often poor.  Many factors have been 
claimed to affect the survival of bifidobacteria in fermented milk products.  These factors 
include pH, hydrogen peroxide level, storage temperature, oxygen content, lactic and acetic 
acid concentrations, sugar concentration (osmotic pressure), milk solids content, buffering 
capacity, β-galactosidase concentration, growth and inhibition factors, amount of inoculums, 
fermentation time, probiotic strain selection, and presence of other microorganisms (Dave 
and Shah 1997; Kailasapathy and others 2008; Donkor and others 2007).  In order to 
overcome these factors various techniques have been employed including strategic culture 
selection, microencapsulation, and the addition of prebiotics (Lourens-Hattingh and Viljoen 
2001; Bruno and others 2002; Capela and others 2006).  The most commonly studied 
prebiotic, inulin, has been shown to improve the survival of a mixed culture of probiotics in 
yogurt during storage at 4 °C (Capela and others 2006).  Beta-glucan, another well known 
prebiotic, has also been postulated to improve probiotic survival in yogurt.  In a recent study, 
researchers found that addition of 0.5 % inulin, oat beta-glucan or barley beta-glucan to 
yogurt resulted in prolonged survival of B. lactis (Vasiljevic and others 2007).  However, 
what was most interesting was that in this study oat beta-glucan out preformed both barley 
beta-glucan and inulin.  Although well understood for the human digestive system, very little 
is known about the mechanism for a prebiotics effect on probiotics during refrigerated 
storage in a food system.  It remains unclear as it if probiotics are able to metabolize the 
prebiotic during storage or if a prebiotic can modulate its surroundings such that it creates a 
more suitable environment for the probiotic. 
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Given the current understanding and great importance of prebiotics and probiotics, 
research was conducted to determine the affect of varying preparations of oat beta-glucan at 
the FDAs minimum therapeutic concentration on two probiotc bifidobacteria strains during 
storage at 4 °C.  The effect of inclusion of a modified corn starch alone and in combination 
with beta-glucan on probiotic survival was also investigated.    
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ABSTRACT:  Probiotics must be consumed at a level of 107CFU/mL for successful 
colonization of the gut. In yogurts containing beneficial cultures, the survival of probiotic 
strains can quickly decline below this critical concentration during cold storage.  The 
inclusion in yogurt of beta-glucan, a possible prebiotic for bifidobacteria also known to have 
heart-healthy effects, would increase the healthfulness of yogurt.  We hypothesized that beta-
glucan would increase the viability of bifidobacteria strains in yogurt during cold storage.  
Yogurts were produced containing 0.44% beta-glucan (concentrated or freeze-dried) 
extracted from whole oat flour and/or 1.33% corn starch, and bifidobacteria (B. breve or B. 
longum) at a concentration of at least 109 CFU/mL.  All yogurts were stored at 4°C.  
Bifidobacteria and yogurt cultures, S. thermophilus and L. bulgaricus, were enumerated from 
undisturbed aliquots before fermentation, after fermentation, and once a week for five weeks.  
S. thermophilus and L. bulgaricus maintained a concentration of at least 108 CFU/mL in 
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yogurts containing concentrated or freeze-dried beta-glucan regardless of starch addition, and 
in the control with no added beta-glucan or starch.  Similarly, the probiotic, B. breve, 
survived above a therapeutic level in all treatments.  The addition of beta-glucan prolonged 
the survival of B. longum at a concentration of at least 107 CFU/mL by up to two weeks on 
average beyond the control.  Further, the inclusion of concentrated beta-glucan in yogurt 
improved survival of B. longum above 107 CFU/mL by one week longer than did freeze-
dried beta-glucan.   Study results suggest that beta-glucan has a protective effect on 
bifidobacteria in yogurt when stressed by low-temperature storage.  The combined benefits 
of the heart-healthy effects from beta-glucan and of the gut-health effects from bifidobacteria 
should provide the food industry with information needed to formulate more healthful yogurt 
products.  
 
INTRODUCTION 
Probiotics are defined as “a preparation of or a product containing viable, defined 
microorganisms in sufficient numbers, which alter the microflora (by implantation or 
colonization) in a compartment of the host and by that exert beneficial health effects in this 
host” (Schrezenmeir and de Vrese 2001). Bifidobacteria, known to act as probiotics, 
naturally occur in the gut of humans, and predominate in the guts of infants; however, as 
infants age their gut flora are soon joined by a variety of other bacteria such as E. coli, 
lactobacilli and clostridia that eventually outnumber bifidobacteria (Candy and others 2008).  
Gut colonization by bifidobacteria falls in adults by 1000-fold after age 60 (van Tongeren 
and others 2005).  This drop in bifidobacteria is associated with an increase in less desirable 
enterobacteriaceae.  Many strains of bifidobacteria have been investigated for possible health 
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benefits, with some of the better documented health benefits including decreased frequency 
and duration of antibiotic-associated diarrhea, as well as positive immunomodulatory 
activity.  Also, colonization in the human gut of the bifidobacteria is postulated to increase 
mineral absorption, prevent hypercholesterolemia, enhance immunity and provide 
anticarcinogenic activity (Fuller 1989; Schrezenmeir and de Vrese 2001).  Indeed, the role of 
bifidobacteria as a part of intestinal flora in maintaining overall health and well-being is not 
fully understood; however, it is recognized that  probiotic cultures must be consumed at a 
level of  at least 107 CFU/mL to provide the therapeutic benefits listed previously (Lourens-
Hattingh and Viljoen 2001).  When probiotics are incorporated into food products, culture 
viability often decreases as a result of low pH, cold temperature stress during storage, lack of 
nutrients, and oxidative stress; thus, it can be a challenge to maintain proper levels of the 
bacteria in food products so the food can deliver the desired amount.  The addition of a 
prebiotic to foods may reduce these stressors and increase probiotic viability during storage 
(Bruno and others 2002; Capela and others 2006; Corcoran and others 2004) . 
 
Prebiotics are defined as “a non-digestible food ingredient that beneficially affects the 
host by selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon” (Gibson and Roberfroid 1995).  Currently, the predominate prebiotic 
used in high fiber foods is the oligofructan, inulin.  Oat beta-glucan has potential advantages 
over inulin as a prebiotic.  Oat beta-glucan is a soluble dietary fiber that reduces serum 
cholesterol, decreases insulin response and can provide prolonged satiety (DeVries 2001; 
Bell and others 1999)   The Food and Drug Administration (FDA) recognizes oat-beta glucan 
for its cholesterol-lowering effects with a health claim (CFR 21, Section 101-81).  According 
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to the FDA, the amount of beta-glucan needed to achieve health benefits in yogurt is 0.75g/6 
oz serving which equates to 0.44% w/w beta-glucan.  In addition, oat beta-glucan has a 
unique high viscosity that can provide desirable textural properties to yogurt (Skendi and 
others 2003).  As a prebiotic, beta-glucan is postulated to improve probiotic survival in 
foods, such as yogurt, however little is known about the relationship between bifidobacteria 
and beta-glucan in a food system during cold storage (Vasiljevic and others 2007).  
Additionally, modified corn starch is often added to yogurts to improve texture.  In 
particular, corn starch greatly improved yogurt viscosity and syneresis when oat beta-glucan 
was included in the formulation (White and Yao 2007).    The impact of corn starch on 
bifidobacteria survival in yogurt was not evaluated.  This study was undertaken to explore 
the relationship between  oat beta-glucan, modified corn starch, and bifidobacteria survival in 
yogurt during refrigerated storage.    
 
The objectives of this study were to investigate the effects of adding oat beta-glucan 
and/or corn starch on the viability of two strains of bifidobacteria in a set-style yogurt during 
5 wk of refrigerated storage.  
 
MATERIALS AND METHODS 
Propagation of Cultures 
 Pure strains of Bifidobacterium breve R0070,  Bifidobacterium longum R0175, 
Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (Institut Rosell Inc., 
Montreal, QC) were  grown anaerobically in de Man Rogosa and Sharpe (MRS broth) broth 
(Fisher Scientific, Pittsburgh, PA) supplemented with 0.22 µm-filter sterilized  0.05% L-
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cysteine (Sigma-Aldrich, St. Louis, MO) for 24 h at 37 °C for two consecutive passes. The 
cultures were then concentrated, 20% glycerol (v/v) was added, and samples were stored in 
cyrovials at -75 °C.  Preliminary results eliminated the use of B. infantis and B. bifidum in 
this study because of their profound fragility during storage at 4 °C. Yogurt starter culture 
strains, Streptococcus thermophilus and Lactobacillus bulgaricus (YC-180, Chr. Hansen, 
Milwaukee, WI), were stored at -20 °C.  Prior to yogurt production both bifidobacteria 
strains were inoculated and propagated twice in MRS broth at 37 °C for 24 h.   
 
Beta-glucan extraction 
An experimental oat line (N979-5-2-4), developed at Iowa State University to have a 
high beta-glucan concentration (7.88%), was grown and harvested at the Agronomy and 
Agricultural Engineering Field Research Center near Ames, Iowa in 2006 (Kim and White 
2009).   The oats were dried and shipped to the Quaker Oats Inc. pilot plant in Cedar Rapids, 
Iowa where they were steamed for one min at 80 °C and rolled to a flake thickness of 0.61 
mm followed by grinding in a Hammer Mill though a 0.56 mm screen.  Beta-glucan was 
extracted from the whole oat flour (Yao and White 2008) and the supernatant collected..  
Extracted beta-glucan was concentrated in a rotary evaporator at 75 °C and 200 mbar until 
the solution reached one-third its starting mass or freeze-dried (-20 °C pre-chill, -26 °C for 
24 h followed by 22 °C for remainder of drying, 80 mbar).  The beta-glucan concentration of 
both treatments was determined by using the Megazyme mixed-linkage beta-glucan assay 
procedure (AACC method 32-23, AOAC method 995.16).   
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Yogurt Preparation 
Yogurt containing 1.5% fat and 11.5% milk-solids not-fat (MSNF) provided the base 
for the treatments (Table 1).  Yogurt treatments containing beta-glucan received a final 
concentration of 0.44% beta-glucan (w/w).  Yogurt treatments containing modified waxy 
corn starch (Thermflo®, National Starch, Bridgewater, NJ) received a final concentration of 
1.33% starch (w/w).  The ingredients were combined, homogenized, and heated at 85 °C for 
30 min.  The yogurt was then cooled to 43 °C and inoculated with yogurt starter culture (200 
mg/L).   The bifidobacteria strains, B. breve, and B. longum, were added, individually, to 
each yogurt treatment at a concentration of at least 109 CFU/mL.  Each treatment was divided 
into 10-mL aliquots and fermented at 42 °C until reaching a pH <4.6, cooled to 4 °C, and 
stored for 5 wks. 
 
Culture viability determination 
To determine cell viability, cell counts were made from aliquots taken prior to 
fermentation (day 0), the day following fermentation (day 1), and once every week for five 
total weeks (days 7-35), each from previously undisturbed yogurt.  Each sample was serially 
diluted in 0.1% peptone water, plated in duplicate on modified MRS agar containing X-α-Gal 
(5-bromo-4-chloro-3-indolyl-α-galactopyranoside) and incubated anaerobically at 37 °C for 
48 h.  The plates were then incubated aerobically an additional 24 h at 22 °C to allow for the 
bifidobacteria color change reaction to occur.  Bifidobacteria (blue) and yogurt culture 
(white) colonies were counted after 72 h (Chevalier and others 1991). 
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Experimental Design 
 For each bacterial strain (B. longum, B. breve, no bifidobacteria added), the 
experiment was conducted as a three-way factorial, with factors (and levels) beta-glucan 
(present, absent), starch (present, absent) and time (0, 1, 7, 14, 21, 28, 35 days).  
Combinations of beta-glucan and starch levels acted as blocks for time.  Each time 
measurement was taken from an independent vial.  Because of space and time constraints, 
half the treatments were completed during one time period and the other half were completed 
during a separate time period.  It is assumed there was no systematic difference in lab 
conditions between the two experimental time periods.  There were three replications for 
each treatment.  Plate counts were done in duplicate for each enumeration time point and 
treatment, with the average log10 colony count used as the response variable for each 
treatment in each replication.   
 
Statistical Analysis 
Data for each bacterial strain were analyzed separately. It was not possible to monitor 
bifidobacteria culture survival below 107 CFU/mL, which affected how data were analyzed 
for each bacterial treatment.  For B. longum and yogurt cultures without bifidobacteria, log10 
colony counts were analyzed using a linear mixed model with normal errors (PROC MIXED 
with restricted maximum likelihood option, SAS 9.1).  Random effects for replicates were 
nested in each experimental time period to reflect the design structure.  Analysis for yogurts 
containing B. longum was based on a logistic random effects model using an indicator 
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variable with a value of 1 if the vial contained a log count above the minimum detection level 
and a value of 0 if the log count was below the minimum detection level.  The parameter 
estimates were obtained using proc GLIMMIX (with restricted maximum likelihood option, 
SAS 9.1).  Thus, for B. longum, observational results as well as estimated detection 
probabilities are reported.  For all cultures, the initial time point before fermentation was 
excluded from statistical analysis.  Significance was set at P ≤ 0.05 using ANOVA F-tests 
and tests of linear contrasts (SAS 9.1).  
 
RESULTS AND DISCUSSION 
Viability of B. breve 
B. breve counts remained above the therapeutic level of 107 CFU/mL over the 5 
weeks of storage for all beta-glucan and starch treatments.  The addition of beta-glucan to 
yogurt containing B. breve had no effect (p = 0.31) on culture viability during cold storage 
(Figure 1).  Furthermore, the addition of starch to yogurt containing B. breve also had no 
effect on culture survival during cold storage (p = 0.85).  However, culture counts during 
cold storage were time dependent (p < 0.01).  This was expected as bifidobacteria are, in 
general, susceptible to cell damage or death when exposed to decreased temperature and pH 
over time.  However, even though B. breve survival was time dependent, average counts 
remained well above the therapeutic threshold, and so, this time dependency is not of 
practical significance.    
The average cell count of B. breve in yogurt containing concentrated or freeze-dried 
beta-glucan was not different from the average count for yogurt containing no beta-glucan (p 
= 0.14 and 0.52, respectively).  Similarly, no differences occurred between the average 
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survival of B. breve in yogurt containing concentrated beta-glucan and the average survival 
of B. breve in yogurt containing freeze-dried beta-glucan (p = 0.36).  In addition, there were 
no significant differences in average B. breve survival between yogurts that did or did not 
contain starch regardless of beta-glucan treatment (p = 0.85).   For all beta-glucan and starch 
treatments the estimated count decreased by 0.00385 log CFU/mL per day.  The lack of 
differences between treatments is not surprising considering the hardiness of this B. breve 
strain.  These results are consistent with a previous study showing that another B. breve strain 
(ATCC 15700) did not differ in growth when grown either aerobically or anaerobically in 
MRS (Bolduc and others 2006).  The lack of differences between treatments containing B. 
breve could indicate that the B. breve strain used may be very aero-tolerant resulting in 
improved survival during the storage period.  The use of an aero-tolerent B. breve strain 
could indicate that any differences in probiotic survival between yogurt treatments may be a 
result of an effect on the dissolved oxygen content of the yogurt or the cultures’ ability to 
provide defense against dissolved oxygen.     
 
Viability of B. longum 
B. longum was much less cold resistant than either B. breve or the mixed yogurt 
cultures.  B. longum did not survive in any treatment for the entire duration of cold storage 
(Table 2).  The longest average survival above 107 CFU/mL occurred in yogurt that 
contained concentrated beta-glucan, either with or without starch, at 21 days.  In yogurt 
containing freeze-dried beta-glucan, with or without starch, the average survival above 107 
CFU/ml was 14 days.  In yogurt containing no beta-glucan or starch, the average survival 
above 107 CFU/mL was 7 days, whereas in yogurt containing starch and no beta-glucan, the 
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average survival above 107 CFU/mL was 1 day.  Because of the sensitivity of B. longum to 
cold storage, many treatment effects were detected.  The data provide strong evidence of an 
effect of both time and beta-glucan treatment on the probability that a count will reach the 
observable level (p < 0.01 and 0.02, respectively).     
These data indicated that the addition of beta-glucan to yogurt increased the survival 
probability of B. longum regardless of starch status, demonstrating that starch, when added in 
combination with beta-glucan or without beta-glucan, did not affect the survival probability 
of B. longum.  The estimated survival probability for B. longum was greater in yogurt 
containing either concentrated or freeze-dried beta-glucan than in yogurt containing no beta-
glucan (p  < 0.01 and  < 0.01, respectively).  This result is consistent with a study done by 
Vasiljevic and others (2007) in which improved survival occurred of  B. animalis (Bb-12™) 
in yogurt containing oat beta-glucan during prolonged cold storage.   B. longum survival 
above 107 CFU/mL was increased by one week on average in yogurt with concentrated beta-
glucan when compared to yogurt with freeze-dried beta-glucan.  Furthermore, the estimated 
survival probability of B. longum in yogurt containing concentrated beta-glucan was greater 
than in yogurt containing freeze-dried beta-glucan (p = 0.03).  The mechanism surrounding 
improved survival of B. longum in the presence of oat beta-glucan remains unknown 
(Vasiljevic and others 2007).  
It is clear that bifidobacteria do not actively divide during cold storage, therefore the 
protective effect of beta-glucan may result from a physical alteration of the environment 
surrounding the probiotic, or from a protective component released during fermentation.  
Thus, the impact might be a protective effect, rather than a prebiotic effect.  As seen 
previously, B. longum was more susceptible to oxygen stress than was B. breve (Bolduc and 
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others 2006).  Another B. longum strain (ATCC 15708) had improved growth in media 
supplemented with ascorbic acid, a known oxygen scavenger, indicating that oxygen status is 
critical for B. longum survival (Bolduc et al., 2006).  Beta-glucan is well known for its 
viscosity-increasing properties.  It could be hypothesized that this physical change may affect 
the matrix such that oxygen penetration is decreased within the yogurt, thus creating a more 
hospitable environment for B. longum.   A benefit to bifidobacteria based on the physical 
alteration of the yogurt environment could explain the benefit of concentrated beta-glucan, 
which remained hydrated and was more easily dispersed, over freeze-dried beta-glucan.    
 
Viability of mixed yogurt cultures S. thermophilus and L. bulgaricus 
In yogurt containing no bifidobacteria, S. thermophilus and L. bulgaricus increased in 
number by an average of 1.7 log10 cycles during fermentation (Figure 2).  During 5 wks of 
storage, the mixed yogurt cultures, S. thermophilus and L. bulgaricus, survived at a level well 
above the therapeutic level of 107 CFU/mL.  High survival of yogurt cultures is consistent 
with studies indicating that S. thermophilus and L. bulgaricus strains survive well during cold 
storage at lowered pH (Saccaro and others 2009; Dave and Shah, 1997; Martensson and 
others 2002).  The cultures, however, positively benefitted from the addition of starch (p <  
0.01).  There was no benefit from the addition of beta-glucan to the yogurt cultures (p = 
0.13), and no difference between average cell counts between yogurt containing concentrated 
and freeze-dried beta-glucan (p = 0.09).  The data also suggest an effect of time on average 
cell counts (p = 0.06) with average cell counts decreasing by 0.00185 log10 CFU/mL each 
day. 
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Yogurt containing B. breve, S. thermophilus and L. bulgaricus increased in number 
by an average of 0.88 log10 cycles during fermentation (Figure 3). Similarly, yogurt 
containing B. longum, S. thermophilus and L. bulgaricus increased in number by an average 
of 0.61 log10 cycles during fermentation (Figure 4).  Thus, the increase during fermentation 
was 0.82 log10 cycles less for yogurt cultures in the presence of B. breve and 1.09 log10 cycles 
less for yogurt cultures in the presence of B. longum, indicating a competitive environment in  
these treatment.  However, yogurt cultures mixed with B. breve or B. longum remained well 
above 107 CFU/mL for the entire the study.   
For yogurt cultures in the presence of B. breve, there was no evidence of an effect of 
beta-glucan, starch, or time on the mean log10 count.  For yogurt cultures in the presence of 
B. longum the data provide  no evidence for an effect of starch, but do provide evidence of an 
effect of beta-glucan (p = 0.27 and 0.05 respectively). The mean log10 count was significantly 
lower for the freeze-dried beta-glucan treatment than for the control (p = 0.02). There was 
also suggestive evidence that the mean log10 count of the yogurt cultures was lower when 
concentrated beta-glucan was added than when no beta-glucan was added (p = 0.08). There 
was no evidence of a difference in the mean log10 counts of the yogurt cultures in the 
presence of B. longum for the concentrated and freeze-dried beta-glucan treatments (p = 
0.39).  From these results we can conclude that in a competitive environment, beta-glucan 
and starch do not provide a benefit to the yogurt cultures when the competitive strain is B. 
breve or B. longum.  Additionally, in a competitive environment where B. longum is the 
competitive strain, beta-glucan may result in lowered average yogurt culture counts. 
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CONCLUSIONS 
Beta-glucan imparted a protective effect on bifidobacteria strains in yogurt when 
stressed by prolonged cold storage.  Inclusion of beta-glucan in yogurt improved B. longum 
survival during storage at 4 °C.  Choice of the bifidobacteria strain as well as the beta-glucan 
preparation method was vital to the increased survival of the probiotic. For example, in the 
case of a very cold sensitive strain, such as B. longum, the addition of beta-glucan increased 
the likelihood that this probiotic would be delivered at a physiologically beneficial level even 
after three weeks of storage at 4 °C.  Although starch had a positive effect on the survival of 
S. thermophilus and L. bulgaricus, there was no effect of starch on the survival of the 
selected bifidobacteria strains.  Questions remain regarding the mechanisms associated with 
the observations in this study; however, these results indicate that the gut-health benefits 
associated with probiotics can be complemented by the heart-health benefits of beta-glucan 
in a yogurt system to provide a doubly healthful product. 
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Table 1. Yogurt base formulations listed as percent of total by mass 
 
  
Ingredient 
(%) 
No β-glucan/ 
No starch 
No β-glucan/ 
Starch 
Concentrated 
β-glucan/ 
No Starch 
Concentrated 
β-glucan/ 
Starch 
Freeze Dried 
β-glucan/ 
No Starch 
Freeze Dried 
β-glucan/ 
Starch 
Cream 3.80 3.80 3.80 3.80 3.80 3.80 
Water 82.00 82.00 80.22 80.22 80.22 80.22 
NFDM 11.38 11.38 11.38 11.38 11.38 11.38 
Sugar 2.83 2.83 2.83 2.83 2.83 2.83 
Beta-glucan - - 0.44 0.44 0.44 0.44 
Corn Starch - 1.33 - 1.33 - 1.33 
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Table 2.  Average viability of B. longum in yogurt treatments with and without beta-glucan (BG) and starch during  
4 °C storage.  Dash indicates that average of three replications fell below the quantifiable level (<107 CFU/mL).   
Standard error not shown due to binary nature of data. 
 Average Cell Count (log10 CFU/mL) 
 
Day 
No β-glucan 
no starch 
No β-glucan 
starch 
concentrated β-
glucan, no starch 
concentrated 
β-glucan, 
starch 
Freeze-dried β-
glucan, no 
starch 
Freeze-dried β-
glucan, starch 
0 9.3 9.2 9.4 9.4 9.3 9.5 
1 9.3 9.4 9.5 9.2 9.5 9.4 
7 8.5 - 9.3 8.8 9.5 9.0 
14 - - 8.8 7.7 8.7 7.8 
21 - - 7.7 8.1 - - 
28 - - - - - - 
35 - - - - - - 
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Figure 1.  Viability of B. breve in yogurt treatments  during 4 °C storage.  BG = beta-glucan, 
conc. = concentrated, FD = freeze-dried.  Error bars represent pooled standard error of the 
mean, SEM = 0.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
7.5
8
8.5
9
9.5
10
0 1 7 14 21 28 35
A
v
e
ra
g
e
 C
e
ll
 C
o
u
n
t 
(L
o
g
 C
F
U
/m
L)
Time (d)
no BG, no starch no BG, starch conc. BG, no starch
conc. BG, starch FD BG, no starch FD BG, starch
44 
 
Figure 2.  Viability of S. thermophilus and L. bulgaricus in yogurt treatments not containing 
bifidobacteria during 4 °C storage.  BG = beta-glucan, conc. = concentrated, FD = freeze-
dried.  Error bars represent pooled standard error of the mean, SEM = 0.07. 
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Figure 3.  Viability of S. thermophilus and L. bulgaricus in yogurt treatments containing B. 
breve during 4 °C storage.  BG = beta-glucan, conc. = concentrated, FD = freeze-dried.  Error 
bars represent pooled standard error of the mean, SEM = 0.12. 
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Figure 4.  Viability of S. thermophilus and L. bulgaricus in yogurt treatments containing B. 
longum during 4 °C storage.  BG = beta-glucan, conc. = concentrated, FD = freeze-dried.  
Error bars represent pooled standard error of the mean, SEM = 0.27. 
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GENERAL CONCLUSIONS 
 
This study demonstrated that the use of oat beta-glucan in yogurt can improve the 
viability of bifidobacteria during refrigerated storage.  B. longum survival above 107 
CFU/mL was improved by one week for treatments containing freeze-dried beta-glucan and 
two weeks for treatments that contained concentrated beta-glucan when compared to the 
control.  Improved survival of B. longum in yogurt with concentrated versus freeze-dried 
beta-glucan may be a result of better beta-glucan dispersion within the yogurt base for the 
concentrated preparation.  Additionally, this study confirmed that for hardy bacteria strains, 
such as B. breve and yogurt cultures, addition of beta-glucan had no detrimental effect on cell 
viability.  Furthermore this study demonstrated that the addition of corn starch, in 
combination with beta-glucan, did not effect bifidobacteria survival during cold storage.   
Mechanisms surrounding the ability of oat beta-glucan to prolong survival of 
sensitive bifidobacteria strains during cold storage still remain unclear.  Mechanisms may 
include modulation of the environment, such that there are more favorable growth conditions, 
possibly decreased dissolved oxygen content, or the mechanism may involve the digestion of 
beta-glucan or the production of a bioactive compound during fermentation.   
 Recommendations for future research include measurement of dissolved oxygen 
content to determine if the mechanism is linked to modulation of the environment and 
creation of a more suitable growth environment by way of decreased dissolved oxygen.  
Additionally,measurements of physical parameters, such as viscosity and/or texture could 
provide useful data.  If the mechanism is related to viscosity, it would be important to know 
how this measurement compared between the treatments.  Finally, it would be prudent to 
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monitor the beta-glucan content after fermentation and during refrigerated storage. There 
would be a decrease in beta-glucan concentration if beta-glucan is consumed by the cultures 
as an energy source.  Continued research is needed to elucidate the appropriate mechanisms. 
This study showed that heart healthy oat beta-glucan can complement the gut-health 
benefits of bifidobacteria to produce a healthful yogurt product.    
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APPENDIX 1 
 
SURVIVAL OF BIFIDOBACTERIA IN LIQUID MEDIA WITH ADDED BETA-
GLUCAN DURING COLD STORAGE 
 
REASONING 
In yogurt prepared with beta-glucan, survival of bifidobacteria was lengthened during 
storage at 4 °C when compared with yogurt with no added beta-glucan.  This experiment was 
designed to test the ability of beta-glucan to protect bifidobacteria from cold stress.  Healthy 
bifidobacteria are able to grow on MRS agar and MRS + 1% NaCl.  Cells weakened or 
damaged by the effects of cold storage are unable to grow on MRS + 1% NaCl.  By 
comparing colony growth on these two types of agar we will be able to differentiate between 
the number of healthy and damaged cells for each treatment.  The difference in plate counts 
between the two types of plating media will tell us if the presence of beta-glucan can 
decrease the number of damaged cells and, in turn, decrease cell death during cold storage.  
 
METHODS  
A series of plating tests were done using fresh and aged (storage for 28 days at 4 °C ) 
bifidobacteria cultures to determine the correct salt concentration needed  to allow for the 
growth of healthy bifidobacteria yet inhibit the growth of damaged  bifidobacteria on MRS 
agar (data not shown).  This concentration was found to be 1% NaCl.   Bifidobacteria 
cultures were obtained and cultured as in chapter 2 methods.  Beta-glucan also was obtained 
and measured as in chapter 2, however, following extraction and concentration or freeze-
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drying, aliquots were vacuumed sealed in plastic sheeting and irradiated at 30.75 kGy/min.  
This was done to ensure sterility during storage.  de Man Rogosa and Sharpe (MRS) broth 
(Fisher Scientific, Pittsburgh, PA) was prepared and treatments were created by the aseptic 
addition and dispersion of concentrated beta-glucan or freeze-dried beta-glucan (0.44% w/v).  
Plain MRS broth served as a control.  Each media treatment was inoculated with either B. 
breve or B. longum (~109 CFU/mL) and 10 mL aliquots were aseptically transferred to sterile 
screw-cap tubes.  Tubes were stored anaerobically at 4 °C.  At each enumeration time point 
each treatment was serially diluted in 0.1% peptone water and plated in duplicate on MRS 
agar and MRS + 1% NaCl agar.  Plates were incubated anaerobically at 37 °C for 48 h and 
colony counts were recorded.  One replication was completed.           
 
RESULTS AND DISCUSSION 
B. breve viability stayed above 107 CFU/mL for all beta-glucan treatments though 
week 4 (Table 1).  At the week 5 time point, B. breve counts dropped below 107 CFU/mL for 
cultures plated on the non-selective MRS agar for all beta-glucan treatments.  However, 
counts above 107 CFU/mL were observed for cultures plated on the selective MRS + 1% 
NaCl agar for all beta-glucan treatments for all time points.  Similarly, B. longum counts 
stayed above 107 CFU/mL for all beta-glucan treatments though week 3 (Table 2).  At the 
week 4 time point, B. longum counts dropped below 107 CFU/mL for cultures plated on the 
non-selective MRS agar for all beta-glucan treatments.  Again, counts above 107 CFU/mL 
were observed for cultures plated on the selective MRS + 1% NaCl agar for all beta-glucan 
treatments for all time points.  These are highly unexpected results, as the MRS + 1% NaCl 
agar was designed to be a much more stressful media for bifidobacteria to grow on.  
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Therefore, we would not expect to see B. breve or B. longum grow on MRS + 1% NaCl and 
not grow on MRS.  From these results we can conclude that the selectivity of the agar was 
not successful.  We cannot, however, make inferences concerning the effect of beta-glucan 
treatments on cold stress or cold damage to B. breve or B. longum.   
 
CONCLUSION 
It was postulated that beta-glucan may have a protective effect on cellular stress or 
damage caused by prolonged cold storage.  Due to the inability to distinguish between 
damaged and healthy bifidobacteria, we were unable to determine if this protective effect 
exists.  It would be prudent to determine another method for examining the effect beta-glucan 
may have on cellular cold stress and damage.       
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Table 1.  Survival of B. breve (log10 CFU/mL) in MRS treated either with or without beta-
glucan plated on non-selective (MRS) and selective (MRS+1%NaCl) media after storage at 
4°C.  Dash indicates a count that fell below quantifiable level (<107 CFU/mL). 
Beta-glucan treatment 
Column1 No beta-glucan Freeze-dried beta-glucan Concentrated beta-glucan 
Plating media 
Week MRS MRS+1%NaCl MRS MRS+1%NaCl MRS MRS+1%NaCl 
0 9.0 9.0 8.9 9.0 8.8 8.8 
1 9.0 8.9 9.0 8.9 8.9 8.8 
2 9.1 9.0 9.0 9.0 9.0 9.0 
3 9.1 9.0 9.0 8.8 9.0 9.0 
4 7.2 7.9 7.3 7.8 7.2 7.9 
5 - 7.3 - 7.3 - 7.4 
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Table 2.  Survival of B.  longum  (log10 CFU/mL) in MRS treated either with or without beta-
glucan plated on non-selective (MRS) and selective (MRS+1%NaCl) media after storage at 
4°C.  Dash indicates a count that fell below quantifiable level (<107 CFU/mL). 
Beta-glucan treatment 
Column1 No beta-glucan Freeze-dried beta-glucan Concentrated beta-glucan 
Plating media 
Week MRS MRS+1%NaCl MRS MRS+1%NaCl MRS MRS+1%NaCl 
0 9.2 9.2 9.3 9.3 9.4 9.3 
1 9.0 8.7 9.2 9.1 9.0 9.0 
2 9.1 9.0 9.1 9.0 9.1 9.1 
3 8.6 8.9 8.9 8.3 8.9 8.6 
4 - 7.5 - 8.1 - 8.0 
5 - 7.8 - 7.6 - 7.8 
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APPENDIX 2 
 
SURVIVAL OF BIFIDOBACTERIA WITH ADDED BETA-GLUCAN THROUGH A 
SIMULATED GASTRIC SYSTEM 
 
 
REASONING 
Beta-glucan has been shown to improve probiotic survival in the large intestine.  As a 
dietary fiber, beta-glucan evades digestion in the stomach and small intestine and is available 
for fermentation by probiotics, such as bifidobacteria, in the large intestine which is known 
as the prebiotic effect.  Studies also suggest that beta-glucan can increase probiotic survival 
during refrigerated storage in yogurt.  The objectives of this study were to determine if beta-
glucan can improve bifidobacteria survival through a simulated human gastric system. 
   
METHODS 
Cultures of B. breve and B. longum were obtained and cultured as in methods from 
chapter 2.  Beta-glucan was also obtained and measured as in chapter 2, however, following 
extraction and concentration or freeze-drying aliquots were vacuumed sealed in plastic 
sheeting and irradiated at 30.75 kGy/min.  This was done to ensure beta-glucan sterility.  
Media was prepared to represent the human gastrointestinal tract in the following way: 
stomach simulated with de Man Rogosa and Sharpe (MRS) broth (Fisher Scientific, 
Pittsburgh, PA) adjusted to pH 3.0 with 20% HCl, upper intestine simulated with MRS broth 
with 0.6% (w/v) oxgall (dehydrated fresh bovine bile) (Difco, Franklin Lakes, NJ) and the 
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colon was simulated with MRS broth with 0.3% (w/v) oxgall.  For treatments containing 
beta-glucan, either concentrated or freeze-dried beta-glucan (0.44% w/w) was added to the 
appropriate media immediately before incubation.  Control media contained no beta-glucan.  
Incubation time in stomach media was 3 hours aerobically, upper intestinal media for 4 hours 
aerobically and colon media for 24 hours anaerobically.  Between each stage of the simulated 
gastrointestinal tract cultures were sampled for plate counts, centrifuged (4300 rpm, 15 min), 
the supernatant was discarded, and the next media was added accordingly.  Aliquots taken 
after each incubation period were diluted in 0.1% peptone water, plated in duplicate on MRS 
agar and incubated anaerobically at 37 °C for 48 hrs after which colonies were counted and 
recorded.  One replication was completed.   
 
RESULTS AND DISCUSSION 
Survival of B. breve though the simulated gastric system remained above 108 
CFU/mL for all treatments (Table 1).  There was no appreciable difference in survival though 
the gastric system between the beta-glucan treatments for B. breve.  These results are not 
surprising considering that previous work has shown that B. breve is a very resilient strain.  
There was no difference in survival of B. longum between the beta-glucan treatments after 
incubation in MRS broth at pH 3 (stomach media).  After incubation in MRS broth +0.6 % 
bile (upper intestine media) B. longum survival remained at 6.0 log10 CFU/mL for the control 
treatment.  However, after this incubation step there was no indication that B. longum had 
survived in treatments that contained either concentrated or freeze-dried beta-glucan.  After 
incubation in MRS + 0.3% bile (colon media) B. longum was found to be 6.8 log10 CFU/mL 
for the control and 2.0 and 1.2 log10 CFU/mL for media containing concentrated and freeze-
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dried beta-glucan respectively.  It was surprising to observe no survival of B. longum through 
a simulated upper intestine and decreased survival through the simulated colon for treatments 
containing beta-glucan.  Although data indicate that beta-glucan may be detrimental to 
survival of probiotic though the gastric system, this may not be so.  The method used in this 
study involved adding beta-glucan to each media before incubation. Because beta-glucan is 
water soluble, it should have been discarded after each centrifugation.  Visual observations 
during this experiment, however, indicated that the beta-glucan may not actually be discarded 
with the supernatant after centrifugation.  Instead the beta-glucan may remain after 
centrifugation, thus leading to an increasing concentration through the simulated gastric 
system.  It is possible that an increasing beta-glucan concentration was responsible for 
hindering the survival of B. longum, which has been shown to be sensitive to environmental 
conditions, and not necessarily the presence of beta-glucan which was intended to be at a 
constant 0.44 % (w/w) concentration.  
Observations of possible beta-glucan accumulation prompted measurement of beta-
glucan in the supernatant from each stage of the simulated gastric system.  As suspected, 
results indicated that very little beta-glucan was found in the supernatant after incubation for 
24 h in MRS and no beta-glucan was found in the supernatant after incubation in stomach 
acid media and 0.6% bile media (Table 2).          
 
CONCLUSION 
Beta-glucan is known to act as a prebiotic for probiotics once it reaches the large 
intestine.  It is possible that though modulation of its fluid environment, beta-glucan may 
have protective effects for probiotics passing through the gastric system.  Unfortunately, 
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these study results do not indicate a benefit to bifidobacteria survival though a simulated 
gastric system given the current methods.  Through the appropriate modifications to the 
methods, to ensure consistent beta-glucan concentration though the gastric system, there may 
be better opportunity to observe a possible protective effect of beta-glucan.   
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Table 1.  Survival (log10 CFU/mL) of B. breve and B. longum through simulated gastric 
system with and without beta-glucan.   
 B. breve B. longum 
Incubation 
Media 
No beta-
glucan 
Concentrated 
beta-glucan 
Freeze-dried 
beta-glucan 
No beta-
glucan 
Concentrated 
beta-glucan 
Freeze-
dried beta-
glucan 
MRS Broth  
(Initial Count) 
 
8.5 8.8 8.8 9.0 9.0 8.9 
MRS Broth 
pH 3 
8.4 8.8 8.5 9.0 9.0 9.0 
MRS Broth + 
0.6% Bile 
8.4 8.8 8.7 6.0 0.0 0.0 
MRS Broth + 
0.3% Bile 
8.2 8.3 8.0 6.8 2.0 1.2 
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Table 2.  Percent beta-glucan in supernatant after and centrifugation in designated incubation 
media.  Percent is average of three measurements taken from cultures of B. breve plus/minus 
standard deviation.   
 
Incubation Mediaon Media 
Beta-glucan Treatment MRS Broth MRS Broth 
pH 3 
MRS Broth 
0.6% bile 
No Beta-glucan -0.040 ± 0.024 -0.064 ± 0.007 -0.042 ± 0.010 
Concentrated Beta-
glucan 
0.126 ± 0.035 -0.004 ± 0.073 0.000 ± 0.037 
Freeze-dried Beta-
glucan 
0.177 ± 0.080 -0.044 ± 0.052 -0.013 ± 0.025 
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